title: Efficacy of Bifidobacterium breve NCC2950 against DSS-induced colitis is dependent on bacterial preparation and timing of administration.
abstract: Probiotics have been proposed as a therapy for inflammatory bowel disease, but variations in strains, formulations, and protocols used in clinical trials have hindered the creation of guidelines for their use. Thus, preclinical insight into the mechanisms of specific probiotic strains and mode of administration would be useful to guide future clinical trial design. In this study, live, heat inactivated (HI), and spent culture medium preparations of the probiotic Bifidobacterium breve NCC2950 were administered to specific pathogen free C57BL/6 mice before or during colitis, as well as before colitis reactivation. Five days of 3.5% dextran sulphate sodium in drinking water was used to induce colitis. Pretreatment with live B. breve reduced disease severity, myeloperoxidase activity, microscopic damage, cytokine production, interleukin (IL)-12/IL-10 ratio, and lymphocyte infiltration in the colon. B. breve did not attenuate on-going colitis. After acute colitis, disease symptoms were normalised sooner with live and HI B. breve treatment; however, reactivation of colitis was not prevented. These findings indicate that the efficacy of a probiotic to modulate intestinal inflammation is dependent on the formulation as well as state of inflammation when administered. Overall, live B. breve was most efficacious in preventing acute colitis. Live and HI B. breve also promoted recovery from diarrhoea and colon bleeding after a bout of acute colitis.
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, 1200 Main St. W., Hamilton, ON L8S 4L8, Canada.
authors.forename: C L
authors.initials: CL
authors.lastname: Hayes
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, 1200 Main St. W., Hamilton, ON L8S 4L8, Canada.
authors.forename: J M M
authors.initials: JM
authors.lastname: Natividad
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, 1200 Main St. W., Hamilton, ON L8S 4L8, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Jury
authors.affiliation: Commensal and Probiotics-Host Interactions Laboratory, INRA, UMR1319 Micalis, 78350 Jouy-en-Josas, France AgroParisTech, UMR Micalis, 78350 Jouy-en-Josas, France.
authors.forename: R
authors.initials: R
authors.lastname: Martin
authors.affiliation: Commensal and Probiotics-Host Interactions Laboratory, INRA, UMR1319 Micalis, 78350 Jouy-en-Josas, France AgroParisTech, UMR Micalis, 78350 Jouy-en-Josas, France.
authors.forename: P
authors.initials: P
authors.lastname: Langella
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, 1200 Main St. W., Hamilton, ON L8S 4L8, Canada.
authors.forename: E F
authors.initials: EF
authors.lastname: Verdu
mesh_terms: D000818:Animals; D001644:Bifidobacterium; D003092:Colitis / Q000139:chemically induced / Q000382:microbiology* / Q000628:therapy; D016264:Dextran Sulfate; D003967:Diarrhea / Q000628:therapy; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000382:microbiology* / Q000628:therapy; D016753:Interleukin-10 / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D007422:Intestines / Q000382:microbiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009195:Peroxidase / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use*; D013047:Specific Pathogen-Free Organisms
chemical_list: C556062:IL10 protein, mouse; D016753:Interleukin-10; D018664:Interleukin-12; D016264:Dextran Sulfate; D009195:Peroxidase
keywords: experimental colitis; inflammation; probiotic